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A B S T R A C T
Background
There are approximately 24 million people worldwide with dementia; this is likely to increase to 81 million by 2040. Dementia
is a progressive condition, and usually leads to death eight to ten years after first symptoms. End-of-life care should emphasise
treatments that optimise quality of life and physicians should minimise unnecessary or non-beneficial interventions. Statins are 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors; they have become the cornerstone of pharmacotherapy for
the management of hypercholesterolaemia but their ability to provide benefit is unclear in the last weeks or months of life. Withdrawal
of statins may improve quality of life in people with advanced dementia, as they will not be subjected to unnecessary polypharmacy or
side effects. However, they may help to prevent further vascular events in people of advanced age who are at high risk of such events.
Objectives
To evaluate the effects of withdrawal or continuation of statins in people with dementia on: cognitive outcomes, adverse events,
behavioural and functional outcomes, mortality, quality of life, vascular morbidity, and healthcare costs.
Search methods
We searched ALOIS (medicine.ox.ac.uk/alois/), the Cochrane Dementia and Cognitive Improvement Group Specialised Register on
11 February 2016. We also ran additional searches in MEDLINE, EMBASE, PsycINFO, CINAHL, Clinical.Trials.gov and theWHO
Portal/ICTRP on 11 February 2016, to ensure that the searches were as comprehensive and as up-to-date as possible.
Selection criteria
We included all randomised, controlled clinical trials with either a placebo or ’no treatment’ control group. We applied no language
restrictions.
Data collection and analysis
Two review authors independently assessedwhether potentially relevant studiesmet the inclusion criteria, using standardmethodological
procedures expected by Cochrane. We found no studies suitable for inclusion therefore analysed no data.
Main results
The search strategy identified 28 unique references, all of which were excluded.
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Authors’ conclusions
We found no evidence to enable us to make an informed decision about statin withdrawal in dementia. Randomised controlled studies
need to be conducted to assess cognitive and other effects of statins in participants with dementia, especially when the disease is
advanced.
P L A I N L A N G U A G E S U M M A R Y
Statin withdrawal in people with dementia
Dementia (including Alzheimer’s disease) is a global healthcare concern; there are approximately 24 million people worldwide with
dementia, and this is likely to increase to 81 million by 2040. Dementia is a slowly progressing condition, and persons affected may
experience a gradual decline over eight to ten years. Medications that are appropriately prescribed when someone has mild dementia
may no longer be appropriate as dementia progresses to severe. Statins are prescribed to lower cholesterol levels in the blood; in most
cases, they help prevent myocardial infarctions (heart attacks) or strokes, but the benefits are only seen after using them for a period
of months or years. They have well known side-effects, such as muscle pain, and it is not known if the benefits of these medications
outweigh the risks in persons with advanced dementia.
Study characteristics
We searched several medical databases on 11 February 2016 to look for clinical trials that compared continuing a statin to withdrawing
a statin, in persons with dementia.
Key findings
We found no studies that were suitable for our review. This highlights the need for further high quality research into this area.
B A C K G R O U N D
Description of the condition
In this review, we were primarily interested in people with estab-
lished dementia due to Alzheimer’s disease (AD), vascular demen-
tia (VaD) or a mix of both (mixed dementia). Other causes in-
cluded dementia with Lewy bodies (DLB) and frontotemporal de-
mentia (FTD). It is estimated there were around 850,000 people
in theUKwith dementia in 2015. There are approximately 24mil-
lion people worldwide with dementia, and this is likely to increase
to 81 million by 2040 (Ferri 2005). It mainly affects people over
the age of 65 (one in 14 people in this age group have dementia),
and the likelihood of developing dementia increases significantly
with age. Alzheimer’s disease is the most common form of de-
mentia, currently affecting more than 520,000 people in the UK;
VaD is the second most common form, affecting approximately
150,000 people in the UK (Alzheimer’s Society 2014). Dementia
is a progressive condition and usually leads to death eight to 10
years after the first symptoms. In the later stages of the disease, peo-
ple become unable to care for themselves and need help with their
daily activities. End-of-life care should emphasise treatments that
optimise quality of life and physicians should minimise unnec-
essary or non-beneficial interventions (Field 1997). Studies have
shown that people with advanced dementia are more likely to be
subject to polypharmacy than healthier persons with a longer life
expectancy, and are at increased risk of inappropriate prescribing
and adverse outcomes as a result of medications (Parsons 2015).
Description of the intervention
Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors. They are among the most widely prescribed
medications in the USA and UK (Goldfine 2012). There are well-
established benefits from this class of drugs: randomised controlled
trials (RCTs) have demonstrated relative risk reductions of 20%
to 30% for myocardial infarction, 20% for ischaemic stroke, and
10% to 15% for all-cause mortality (Baigent 2005). However, for
most indications, the benefits of these drugs are only realised after
a period of months or years (Holmes 2009). They have become the
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cornerstone of pharmacotherapy for the management of hyperc-
holesterolaemia, but their ability to provide benefit is unclear in
the last weeks or months of life. Older people living in residential
care commonly take statins, with one study showing 33% of resi-
dents over 70 years of age were prescribed statins (Gnjiidic 2015).
Continuation of statins in advanced dementia may be viewed as
futile, and may contribute unnecessary distress to patients who
have a high level of functional disability and eating dysfunction.
Whilst many symptoms (e.g. sore throat, nosebleeds, nausea, aller-
gic rhinitis, altered bowel habits) have been attributed to statins,
the adverse effects from RCTs have generally been fewer, and in-
clude small increases in the incidence of myopathy, diabetes, and
probably, hemorrhagic stroke (CTT Collaboration 2016). There
is also a concern about possible cognitive harm from statins; in
the USA, the Food and Drug Administration (FDA) issued new
labelling rules in 2012, adding information on the potential for
generally non-serious and reversible cognitive side effects. On the
other hand, a network meta-analysis of 246,955 participants from
135 RCTs concluded that as a class, adverse events associated with
statin therapy are not common (Naci 2013). There is a lack of
evidence for cognitive benefit from statins in both treatment and
prevention of dementia (McGuinness 2014; McGuinness 2016).
Withdrawal of statins may improve quality of life in people with
advanced dementia as they will not be subject to unnecessary
polypharmacy or the side effects mentioned. However, they may
help prevent further vascular events in people of advanced age who
are at high risk of such events; a meta-analysis has demonstrated
that each 1 mmol/L decrease in LDL cholesterol equates to a re-
duction in relative risk for stroke of 21% (Amarenco 2009).
How the intervention might work
Statin withdrawal may contribute to an improved quality of life
in people with advanced dementia, which is a positive outcome,
but may conversely lead to more non-fatal or fatal vascular events.
Why it is important to do this review
The value of statins in preventing heart disease and ischaemic
stroke is well established. For individuals with life-limiting ill-
ness, such as advanced dementia, an expert consensus panel has
suggested that certain medications, such as statins, may be inap-
propriate when the goal of care is comfort (Holmes 2008). Few
studies have examined statin use as death approaches in advanced
dementia. Prior studies of nursing-home residents with advanced
dementia showed that 12% to 16% used a lipid-lowering drug,
and that one-third discontinued that drug in the last weeks of life
(Tjia 2010; Tjia 2014). A prospective cohort study of medica-
tion in National Health residents with advanced dementia found
a significant number of people were still being prescribed statins
towards the end of their life (Blass 2008), while In a recent feasi-
bility study, a consensus panel of expert clinicians from Northern
Ireland rated the use of statins as never appropriate in advanced
dementia (Parsons 2015). Statins also frequently contribute to
polypharmacy, which in itself has been shown to increase mor-
tality in nursing-home residents with advanced cognitive impair-
ment at the end of life (Onder 2013). One study group has ad-
vocated that in the absence of a recent acute coronary syndrome
or cerebrovascular event, the discontinuation of a statin towards
the end of life is reasonable (Vollrath 2005). It may be the case
that a watershed moment is reached, when the disease reaches a
threshold of severity, and the risks outweigh the benefits of the
medications (Bowman 2014). Due to the frequency with which
statins are prescribed to people with advanced dementia, there is
a need for further research into the benefits, risks, and effects on
quality of life if these medications are to be discontinued towards
the end of life.
O B J E C T I V E S
To evaluate the effects of withdrawal or continuation of statins
in people with dementia on: cognitive outcomes, adverse events,
behavioural and functional outcomes, mortality, quality of life,
vascular morbidity, and healthcare costs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised, controlled clinical trials. We included withdrawal
trials that were not placebo-controlled, and evaluated them for
bias. We applied no language restrictions.
Types of participants
• All people with a diagnosis of dementia, as defined by a
recognised and validated tool or clinical assessment, and taking
any type of statin. Eligible dementia subtypes are AD, VaD,
mixed dementia, DLB and FTD.
• People with a diagnosis of probable or possible AD,
according to National Institute of Aging-Alzheimer’s Association
2011 criteria (McKhann 2011), or acceptable equivalent.
• People with a diagnosis of probable or possible VaD,
according to National Institute of Neurological Disorders and
Stroke/Association Internationale pour la Recherché et
l’Enseignement en Neurosciences (NINDS-AIREN) criteria
(Román 1993), or acceptable equivalent.
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• People with a diagnosis of probable or possible DLB,
according to international consensus criteria for DLB (McKeith
2005).
• People with a diagnosis of probable or possible FTD
according to Neary criteria (Neary 1998).
Participants may reside in any healthcare setting, including acute
hospitals, nursing and residential homes and the community.
Types of interventions
Intervention: Withdrawal or dose reduction of statin or placebo.
Comparison: Continuation of statin.
Types of outcome measures
Primary outcomes
• Cognition (Mini Mental State Examination (MMSE) or
equivalent).
• Adverse effects of statin medications.
Secondary outcomes
• Function (Barthel Activities of Daily Living or equivalent),
behaviour, mortality, vascular morbidity (stroke, myocardial
infarction (MI)), and quality-of-life outcomes, measured with
validated scales.
• Hospitalisation.
Search methods for identification of studies
Electronic searches
We searched
ALOIS (www.medicine.ox.ac.uk/alois/), the Cochrane Dementia
and Cognitive Improvement Group (CDCIG) Specialised Reg-
ister on 11 February 2016. We went through all possible statin
withdrawal trials to identify any that had cognitive outcomes.
ALOIS is maintained by the Information Specialist for the
Cochrane Dementia and Cognitive Improvement Group, and
contains studies that fall within the areas of dementia prevention,
dementia treatment andmanagement, and cognitive enhancement
in healthy elderly populations. The studies are identified through:
1. Monthly searches of a number of major healthcare
databases: MEDLINE, EMBASE, CINAHL, PsycINFO and
LILACS;
2. Monthly searches of a number of trial registers:
International Standard Randomised Controlled Trials Number
(ISRCTN); UMIN (Japan’s Trial Register); the WHO portal
(which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical
Trials Register; the German Clinical Trials Register; the Iranian
Registry of Clinical Trials and the Netherlands National Trials
Register, plus others);
3. Quarterly search of the Cochrane Central Register of
Controlled Trials (CENTRAL);
4. Six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to
Theses; Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS.
Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia, cognitive
improvement, and cognitive enhancement trials, can be viewed in
the ‘Methods used in reviews’ section within the editorial informa-
tion about the Cochrane Dementia and Cognitive Improvement
Group.
We ran additional searches in MEDLINE, EMBASE, PsycINFO,
CINAHL, Clinical.Trials.gov, and theWHOPortal/ICTRPon11
February 2016, to ensure that the searches were as comprehensive
and as up-to-date as possible. The search strategy that we used for
the retrieval of reports of trials from MEDLINE (via the Ovid SP
platform) can be seen in Appendix 1.
Searching other resources
We reviewed citations of reference lists of included studies iden-
tified through the search strategy described above, and assessed
their suitability for inclusion in the review. We did not apply any
language restrictions.
Data collection and analysis
We designed the methods in this review in accordance with rec-
ommendations in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Selection of studies
Two review authors (BMcG and PP) independently screened titles
and abstracts. Both review authors agreed on and tested theMeSH
terms and search strategy. They both independently selected trials
for relevance against the defined inclusion criteria. They retrieved
in full text any papers identified as potentially relevant by at least
one review author; both review authors independently reviewed
the papers against the inclusion criteria, and reached a final de-
cision through consensus. We listed all papers excluded from the
review at the full-text stage as excluded studies, with reasons pro-
vided in the ’Characteristics of excluded studies’ table. We did not
identify any ongoing RCTs that met our inclusion criteria. In fu-
ture updates of this review, we will employ the methods detailed
in the ’Differences between protocol and review’ section below.
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Data extraction and management
Not applicable
Assessment of risk of bias in included studies
Not applicable
Measures of treatment effect
Not applicable
Unit of analysis issues
Not applicable
Dealing with missing data
Not applicable
Assessment of heterogeneity
Not applicable
Assessment of reporting biases
Not applicable
Data synthesis
Not applicable
Subgroup analysis and investigation of heterogeneity
Not applicable
Sensitivity analysis
Not applicable
R E S U L T S
Description of studies
Not applicable
Results of the search
Electronic searches retrieved 28 abstracts. We obtained four full
papers in full-text form. No studies were eligible for inclusion.
Included studies
No studies met our inclusion criteria.
Excluded studies
We excluded four studies after examination of the full text (Padala
2010; Padala 2012; Tjia 2014; Kutner 2015). See also the ’Char-
acteristics of excluded studies’ table.
Padala 2010 was a retrospective chart review carried out on 55
patients with dementia or mild cognitive impairment who were
receiving statin treatment at the initial visit. Twenty-four subjects
had their statin discontinued at the initial visit; they had a MMSE
at baseline but only eighteen had a repeat MMSE at follow-up.
Mean length of follow-up was 4.8 weeks, SD 1.4 weeks.There
was an apparent improvement in cognition in those who stopped
taking statins, but there were no MMSE scores provided for those
who continued taking statins, so a direct comparison was not
available. The study was not randomised, included no cognitive
information on the control group, was not blinded, had a short
duration, and small sample size, so was not suitable for inclusion
in the review.
Padala 2012 was a twelve-week prospective open-label study. Eigh-
teen older subjects with Alzheimer’s disease underwent a six-week
withdrawal phase from statins, followedby a six-week re-challenge.
This pilot study showed an improvement in cognition, as mea-
sured by the MMSE, with discontinuation of statins and worsen-
ing with re-challenge. The study was not randomised, included
no control group, was not blinded, had a small sample size, and
short duration, so was not suitable for inclusion.
Tjia 2014 was a retrospective inception cohort study, therefore, did
not meet inclusion criteria for this review. There were no cognitive
or adverse effect outcomes reported. Nursing home residents with
advanced dementia were observed from baseline and followed for
at least ninety days to statin discontinuation or death. In follow-
up, 37.2% of nursing home residents with advanced dementia
discontinued statins. Median time to discontinuation was 36 days
(interquartile range 12 to 110 days). Shorter time to discontinu-
ation was associated with hospitalisation in the past thirty days,
and more daily medications.
Kutner 2015 was a multicenter, parallel-group, unblinded prag-
matic clinical trial with 381 participants. Eligible participants were
English speaking adults (at least 18 years old) receiving a statin
for at least three months, for primary or secondary prevention
of cardiovascular disease. Eligible participants had a documented
diagnosis of advanced, life-limiting illness, determined by (1) at
least one physician indicating he or she ’would not be surprised if
the patient died in the next year’, (2) life expectancy between one
month and one year, and (3) recent deterioration in functional
status. Participants were randomised to either discontinue or con-
tinue statin therapy, and were monitored monthly for up to one
year. Twenty-seven per cent of the statin discontinuation group
and 17.2% of the statin continuation group were cognitively im-
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paired at baseline. There was no subgroup analysis carried out in
those who were cognitively impaired, so the study did not meet
inclusion criteria for this review; the study authors were contacted,
but could not provide data on the cognitively impaired subgroup.
Risk of bias in included studies
No study met the eligibility criteria
Effects of interventions
No study met the eligibility criteria
D I S C U S S I O N
Summary of main results
There were no clinical trials suitable for inclusion in this review,
highlighting the need for further research in this area. Contro-
versy remains regarding the use of statins in people with advanced
dementia. Four studies were excluded due to study design. Ran-
domised controlled double-blind studies with a larger sample size
and a longer duration need to be conducted to assess the cognitive
effects of statins in participants with dementia, especially when
the disease is advanced.
Overall completeness and applicability of
evidence
There were no randomised controlled trials, so evidence is lacking.
Quality of the evidence
No studies met the inclusion criteria for this review, so there is no
evidence to assess.
Potential biases in the review process
Our search terms did not include some recent favoured terminolo-
gies such as deprescribing, and there are no specific search filters
related to deprescribing; this is something we will work on for
future reviews.
We were unable to check for publication bias, as we did not find
any studies that met our inclusion criteria.
Agreements and disagreements with other
studies or reviews
Other reviews have assessed the impact of statin treatment on cog-
nition in general (Richardson 2013; Kelley 2014; Ott 2015), but
none have assessed statin withdrawal in participants with demen-
tia.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We are unable to make any evidence-based recommendations, as
we found no suitable studies that assessed the impact of statin
withdrawal in patients with dementia.
Implications for research
High quality RCTs are required in this area, whereby patients
with advanced dementia are randomised so that the intervention
is withdrawal of the statin and continuation of the usual statin
is the control. Ideally, studies should assess the impact of statin
withdrawal on cognition, adverse effects, and other secondary out-
comes, such as physical function, behaviour, mortality, vascular
morbidity, quality of life, and hospitalisation rate. Prior studies
have reported that more than 90% of proxies of nursing home
residents with advanced dementia state that their goal of care is
comfort (Luchins 1993; Mitchell 2009). Statins do not promote
comfort, so their role in the case of advanced dementia may not be
warranted, but evidence is lacking. A further trial will most likely
require government or charity funding, as statin manufacturers
are unlikely to fund such a trial. If it is proven that withdrawal
of statins is of benefit in advanced dementia, the money saved
could be used in effective but underused interventions, thereby
contributing towards affordable healthcare.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Kutner 2015 No cognitive or adverse effects outcomes. 27% of participants in the discontinuation group and 17.2% in the
continuation of statins group were cognitively impaired, but there was no subgroup analysis carried out
Padala 2010 Retrospective case note study.
Padala 2012 Not randomised, no control group, not blinded.
Tjia 2014 Retrospective inception cohort study.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. (statin or statins).ti,ab.
2. atorvastatin.ti,ab.
3. cerivastatin.ti,ab.
4. fluvastatin.ti,ab.
5. lovastatin.ti,ab.
6. pravastatin.ti,ab.
7. simvastatin.ti,ab.
8. lipitor.ti,ab.
9. baycol.ti,ab.
10. lescol.ti,ab.
11. mevacor.ti,ab.
12. altocor.ti,ab.
13. pravachol.ti,ab.
14. lipostat.ti,ab.
15. zocor.ti,ab.
16. mevinolin.ti,ab.
17. compactin.ti,ab.
18. fluindostatin.ti,ab.
19. rosuvastatin.ti,ab.
20. Hydroxymethylglutaryl-CoA Reductase Inhibitors/ or Lovastatin/
21. Simvastatin/
22. or/1-21
23. randomized controlled trial.pt.
24. controlled clinical trial.pt.
25. randomized.ab.
26. placebo.ab.
29. drug therapy.fs.
30. randomly.ab.
31. trial.ab.
32. groups.ab.
33. or/44-52
34. (animals not (humans and animals)).sh.
35. 32 not 33
36. 22 and 34
37. discontinu*.mp.
38. withdraw*.mp.
39. cessat*.mp.
40. (reduce* or reducing* or reduct*).mp.
41. taper*.mp.
42. stop*.mp.
43. “carry on”.mp.
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44. continu*.mp.
45. maintain*.mp.
46. remain*.mp.
47. or/35-46
48. 35 AND 47
C O N T R I B U T I O N S O F A U T H O R S
BMcG: all work concerned with the review
PP: selection of studies, commenting on draft review
CC: Statistical advice, commenting on draft review
D E C L A R A T I O N S O F I N T E R E S T
BMcG: none known
PP: none known
CC: none known
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NIHR, UK.
This review was supported by the National Institute for Health Research, via a Cochrane Programme Grant to the Cochrane
Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do not
necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Assessment of risk of bias in included studies
Two review authors (BMcG and PP) will independently assess risk of bias for each of the included studies, using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We will resolve any disagreements by discussion, or if
necessary, we will involve the third review author (CC).We will assess the following domains: selection bias, performance bias, detection
bias, attrition bias, and reporting bias. We will carry out sensitivity analyses to determine inclusion or exclusion of low-quality studies.
(1) Random sequence generation (checking for possible selection bias)
We will describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We will assess the risk of bias for sequence generation as:
• low risk (any truly random process, e.g. random-number table; computer random-number generator);
• high risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
• unclear risk.
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(2) Allocation concealment (checking for possible selection bias)
We will describe for each included study the method used to conceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment.
We will assess the risk of bias for allocation concealment as:
• low risk (e.g. telephone or central randomisation; consecutively-numbered sealed opaque envelopes);
• high risk (e.g. open random allocation; unsealed or non-opaque envelopes; alternation; date of birth);
• unclear risk.
(3.1) Blinding of participants and personnel (checking for possible performance bias)
We will describe for each included study the methods used, if any, to blind study participants and personnel to knowledge of which
intervention a participant received. We will consider that studies are at low risk of bias if they were blinded.
We will assess the risk of bias for blinding of participants and personnel as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible detection bias)
We will describe for each included study the methods used, if any, to blind outcome assessors to knowledge of which intervention a
participant received.
We will assess the risk of bias for blinding of outcome assessment as:
• low risk;
• high risk;
• unclear risk.
(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome, the completeness of data including attrition and exclusions from the
analysis. We will state whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared
with the total number of randomised participants), reasons for attrition or exclusion where reported, and whether missing data were
balanced across groups or were related to outcomes. Where sufficient information is reported, or can be supplied by the trial authors,
we will re-include missing data in the analyses that we undertake. We will assess the risk of bias for incomplete outcome data as:
• low risk (e.g. no missing outcome data; missing outcome data balanced across groups);
• high risk (e.g. frequency of or reasons for missing data that are unbalanced across groups);
• unclear risk.
(5) Selective reporting (checking for reporting bias)
We will investigate the possibility of selective outcome reporting bias by cross-checking outcomes of interest reported in the Methods
section to those reported in the Results section of the trial publications. We will assess the risk of bias for selective reporting as:
• low risk (where it is clear that all of the prespecified outcomes and all expected outcomes of interest to the review have been
reported);
• high risk (where not all the prespecified outcomes have been reported; one or more reported primary outcomes were not
prespecified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that
would have been expected to have been reported);
• unclear risk.
(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)
We will describe for each included study any important concerns we have about other possible sources of bias.We will assess the risk of
other forms of bias as:
• low risk;
• high risk;
• unclear risk.
(7) Overall risk of bias
Wewill make explicit judgements about whether studies are at high risk of bias, according to the criteria given in theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). With reference to (1) to (6) above, we will assess the likely magnitude and
direction of the bias and whether we consider it is likely to impact the findings. We will explore the impact of the level of bias by
undertaking sensitivity analyses (see Sensitivity analysis), and we will assess the overall risk of bias for each included study as:
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• low risk;
• high risk;
• unclear risk.
Measures of treatment effect
Continuous data: We will extract themean change from baseline, the standard error of themean change, and the number of participants
for each treatment group at each assessment. Where change from baseline is not reported, we will extract the mean, standard deviation
(SD), and the number of participants for each treatment group at each time point. We will also extract available data on demographics
of participants (age, gender, lipid values at baseline), statin regimen (type of statin, daily dosage, starting time, duration), and follow-
up duration. We will report the difference, mean, and 95% confidence interval (CI).
Dichotomous data: For binary data (e.g. statin or not), we will seek the numbers in each treatment group and the numbers experiencing
the outcome of interest. We will report results as an odds ratio (OR) with 95% CI.
Wewill use theGRADE approach to assess the quality of the supporting evidence behind each estimate of treatment effect (Schünemann
2011). We will present key findings of the review, including a summary of the amount of data, the magnitude of the effect size, and
the overall quality of the evidence, in a ’Summary of findings’ table, created using GRADEpro software (GRADEproGDT 2015). We
have preselected the following outcomes: cognition, function, behaviour, mortality, vascular morbidity, and quality of life.
Unit of analysis issues
Studies with multiple treatment groups: If a study involves more than two treatment groups, we will exclude any treatment groups not
relevant to the review objectives. If more than two groups are relevant to a single meta-analysis, we will combine groups to form single
experimental and control groups.
Dealing with missing data
For included studies, we will note levels of attrition. We will explore the impact of including studies with high levels of missing data
(we judge this a priori to be greater than 20% for a primary outcome) in the overall assessment of treatment effect by conducting a
sensitivity analysis.
For all outcomes, we will carry out analyses as far as possible on an intention-to-treat basis. If intention-to-treat data are not available
in the publications, we will use complete-case data, i.e. the data for those who completed the trial. If neither intention-to-treat nor
complete-case data are available, we will use ’on-treatment’ data, and will make this clear.
Assessment of heterogeneity
Where studies are considered similar enough (based on consideration of populations and interventions) to allow pooling of data
using meta-analysis, we will assess the degree of heterogeneity by visual inspection of forest plots and by examining the Chi² test for
heterogeneity. We will assess statistical heterogeneity in each meta-analysis using the I² and Chi² statistics. With regard to statistical
heterogeneity, we will rate an I² statistic of up to 30% as possibly not important, of 30% to 60% as moderate, 50% to 90% as substantial,
and 75% to 100% as considerable (IQWIG 2015). We will prefer tau² over I² in the interpretation of between-trial heterogeneity, as the
interpretation of I² can be largely affected by the precision of trials included in the meta-analysis (Rucker 2008). We pre specify a Tau²
of 0.04 to represent low heterogeneity, 0.09 to represent moderate heterogeneity, and 0.16 to represent high heterogeneity between
trials (Spiegelhalter 2004).
Where we identify substantial clinical, methodological, or statistical heterogeneity across included studies, we will consider whether it
is appropriate to report a pooled effect result from the meta-analysis, or to use a narrative approach to synthesise data. In this event, we
will attempt to explore possible reasons for the heterogeneity by grouping studies that have similar populations and interventions.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis, we will investigate reporting biases (such as publication bias) using funnel plots.
We will visually assess funnel plot asymmetry. If this suggests asymmetry, we will perform exploratory analyses to investigate it. We
acknowledge that publication bias may not be the only cause of funnel plot asymmetry. If a small-study effect is apparent, we will
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explore other potential reasons, for example diversity in methodological quality, bias, and genuine heterogeneity in the intervention
effect. We will investigate other possible causes by undertaking a sensitivity analysis (Sterne 2011).
We will also verify trial details and outcomes against trial descriptions identified in trial registries.
Data synthesis
We will carry out statistical analysis using the Review Manager 5 software (RevMan 2014). If there is clinical heterogeneity sufficient
to expect that the underlying treatment effects differ between trials, or if we detect substantial statistical heterogeneity (Tau² greater
than 0.16), we will use a random-effects model meta-analysis to produce an overall summary, provided that we consider an average
treatment effect across trials to be clinically meaningful. We will treat the random-effects model summary as the average treatment
effect, and we will discuss the clinical implications of treatment effects differing between trials. If the average treatment effect is not
clinically meaningful, we will not combine trials.
If we use random-effects model analyses, we will present the results as the average treatment withdrawal effect with a 95% CI and with
the estimate of Tau² and I².
We will only use a fixed-effect model meta-analysis for combining data where it is reasonable to assume that studies are estimating the
same underlying treatment effect, i.e. where we judge participants, interventions, and methods to be sufficiently similar.
Subgroup analysis and investigation of heterogeneity
Where data are available, we will conduct an analysis based on relevant and clinically meaningful subgroups such as class of statins
(lipophilic versus hydrophilic); low versus high doses of statins; and duration of use: short-term use (less than one month of cumulative
use), intermediate-term use (one month or more, but less than 24 months of cumulative use); and long-term use (more than two years
cumulative use).
We will conduct an analysis based on the degree of dementia severity: severe, moderate, or mild as defined by clinical judgement or
MMSE cut-off scores (less than 12, 12 to 20, more than 20/30 respectively). Where this is not explicit, we will request data on severe
or not severe from study authors.
We will assess subgroup differences by interaction tests available within RevMan 2014. We will report the results of subgroup analyses
quoting the Chi² statistic and P value, and the interaction test I² value.
Sensitivity analysis
If heterogeneity persists with either model, we will carry out a sensitivity analysis (excluding studies with a high risk of bias), thereby
assessing the robustness of the results.
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